



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## Zipper method is the emerging treatment option for severe Guillain-Barre syndrome related COVID-19

Dear Editor;

We read the article of Hussain et al. with great interest [1]. The authors discussed very clearly a possible relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and Guillain-Barre syndrome (GBS) in a pathophysiological aspect which is mostly implicated by the cytokine release storm. Accordingly, severe SARS-CoV-2 infection and GBS share the similar immunological profile. Corticosteroids may be a good immunosuppressive choice for acting via multiple pathways. They have also pointed out that corticosteroids had not been observed enough in patients with severe GBS related Coronavirus disease 2019 (COVID-19) and should be kept in mind when other conventional therapies such as plasmapheresis and intravenous immunoglobulin (IVIG) failed.

While we appreciate the efforts of the authors, we think that preferred immunomodulatory therapy for those severe GBS patients should be Zipper Method. Zipper Method is the emerging treatment option for severe GBS patients [2]. Zipper Method consists of rigorous implementation of plasmapheresis and IVIG in an interpenetrating manner [3]. Plasmapheresis clears the autoantibodies and cytokines and prompt administration of IVIG after plasmapheresis session neutralizes antibodies that are regenerated and transited from tissue. The subsequent PE session sweeps away the soiled antibodies. This way of ranking leads to a consistency of both regimens augmenting each other's effect [3]. In severe COVID-19 patients the inflammatory mediators, especially IL-6 unveiling the cytokine chaos peak up around 7–14 days after onset. Early administration of plasmapheresis is also beneficial in alleviating COVID-19 related cytokine storm [4].

The Zipper Method reduces mortality, speeds up weaning from mechanical ventilation and shortens hospital stay with an excellent outcome in severe GBS patients with axonal involvement. Zipper Method provided shortened mechanical ventilation durations (mean 7 days) and length of stay (mean 18 days) in our case series of severe GBS with full recovery in 28 days [3].

We suggest Zipper Method as a further immunomodulation technique to be the preferred treatment option for COVID-19 related GBS patients as it promises better outcomes for both scenarios with severe presentation.

### Funding

None.

### Declaration of Competing Interest

None.

### References

- [1] Hussain FS, Eldeeb MA, Blackmore D, Siddiqi ZA. Guillain Barre syndrome and COVID-19: possible role of the cytokine storm. *Autoimmun. Rev.* 2020;19(12): 102681.
- [2] Shang P, Zhu M, Wang Y, Zheng X, Wu X, Zhu J, et al. Axonal variants of Guillain-Barre syndrome: an update. *J. Neurol.* 2020 (Online ahead of print).
- [3] Kesici S, Tanyildiz M, Yetimakan F, Bayrakci B. A novel treatment strategy for severe Guillain-Barre syndrome: zipper method. *J. Child Neurol.* 2019;34(5): 277–83.
- [4] Kesici S, Yavuz S, Bayrakci B. Get rid of the bad first: therapeutic plasma exchange with convalescent plasma for severe COVID-19. *Proc. Natl. Acad. Sci. U. S. A.* 2020; 117(23):12526–7.

Ozlem Saritas Nakip<sup>\*</sup>, Selman Kesici, Benan Bayrakci  
*Department of Pediatric Intensive Care, Hacettepe University Faculty of Medicine, Ankara, Turkey*

<sup>\*</sup> Corresponding author at: Department of Pediatric Intensive Care, Hacettepe University Faculty of Medicine, İhsan Doğramacı Children's Hospital, Altındağ, Ankara 06230, Turkey.  
*E-mail address:* [saritas.ozlem@hacettepe.edu.tr](mailto:saritas.ozlem@hacettepe.edu.tr) (O. Saritas Nakip).